Asa Elmore | Sutro Biopharma, Inc.

2023 American Society of Pediatric Hematology / Oncology (ASPHO) Annual Meeting – Poster

2023 American Society of Pediatric Hematology / Oncology (ASPHO) Annual Meeting – Poster A Novel Therapy for Refractory CBFA2T3::GLIS2-associated AMKL Using STRO-002 And Plerixafor...

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

News, Press Releases

Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones – Data from the Phase 1 dose-expansion study for luveltamab tazevibulin, or luvelta, for patients with advanced ovarian cancer will be featured as...

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

Events, News, Presentations, Press Releases

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference SOUTH SAN FRANCISCO, Calif., May 8, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug...

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

News, Press Releases

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer SOUTH SAN FRANCISCO, Calif., April 27, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and...

2023 American Association for Cancer Research Annual Meeting (AACR) – Poster

Events, News, Presentations

2023 American Association for Cancer Research Annual Meeting (AACR) – Poster Abstract #4849: The anti-ROR1 ADC STRO-003 demonstrates immune-modulating properties that may enhance checkpoint blockade Andrew McGeehan, Sihong Zhou, Dayson Moreira, Robert Yuan, Indrani...

« Older Entries